Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

More Details about Hisun-Pfizer and Merck-Simcere JVs

publication date: May 20, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
In 2011, the world’s two largest drugmakers – Pfizer and Merck – each announced major China drug JVs with domestic China pharmas – Hisun in Pfizer’s case and Simcere for Merck. The arrangements were high-profile, and their aims went beyond drug distributorship, reaching into drug development. But details have been slow to emerge. A recent article in People’s Daily shed some light on these important JVs, which are now just getting under way. More details....

Stock Symbols: (NYSE: PFE) (NYSE: MRK) (SHA: 600267) (NYSE: SCR)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...